Serum levels of anti-β2GPI antibodies
| Mice characteristics . | Values . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, wk | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| Females, μg/mL | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.7 | 0.7 | 0.7 |
| (n = 10) | (n = 5) | (n = 10) | (n = 10) | (n = 14) | (n = 16) | (n = 12) | (n = 12) | (n = 22) | (n = 11) | (n = 15) | (n = 17) | (n = 8) | |
| Males, μg/mL | 1.9 | 1.4 | 5.5 | 5.4 | 5.9 | 5.4 | 6.6 | 6.3 | 7.9 | ||||
| (n = 12) | (n = 7) | (n = 12) | (n = 12) | (n = 27) | (n = 17) | (n = 8) | (n = 4) | (n = 6) | |||||
| P* | .007 | .04 | .0002 | .0001 | <.0001 | <.0001 | .0001 | .005 | .0003 | ||||
| Mice characteristics . | Values . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, wk | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| Females, μg/mL | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.7 | 0.7 | 0.7 |
| (n = 10) | (n = 5) | (n = 10) | (n = 10) | (n = 14) | (n = 16) | (n = 12) | (n = 12) | (n = 22) | (n = 11) | (n = 15) | (n = 17) | (n = 8) | |
| Males, μg/mL | 1.9 | 1.4 | 5.5 | 5.4 | 5.9 | 5.4 | 6.6 | 6.3 | 7.9 | ||||
| (n = 12) | (n = 7) | (n = 12) | (n = 12) | (n = 27) | (n = 17) | (n = 8) | (n = 4) | (n = 6) | |||||
| P* | .007 | .04 | .0002 | .0001 | <.0001 | <.0001 | .0001 | .005 | .0003 | ||||
Median of concentrations of anti-β2GPI antibodies measured in (NZW × BXSB)F1 mice at different age. The statistical significance of the changes in the concentration of anti-β2GPI antibodies in serum samples of mice at different age and gender is compared using the Wilcoxon rank-sum test.
P values for the differences between serum levels of anti-β2GPI antibodies in the blood samples of female and male (NZW × BXSB)F1 mice at indicated age.